[go: up one dir, main page]

AR065081A1 - FUSIONATED QUINAZOLINONA AND PIRIMIDONA COMPOUNDS AND PHARMACEUTICAL COMPOSITION - Google Patents

FUSIONATED QUINAZOLINONA AND PIRIMIDONA COMPOUNDS AND PHARMACEUTICAL COMPOSITION

Info

Publication number
AR065081A1
AR065081A1 ARP080100362A ARP080100362A AR065081A1 AR 065081 A1 AR065081 A1 AR 065081A1 AR P080100362 A ARP080100362 A AR P080100362A AR P080100362 A ARP080100362 A AR P080100362A AR 065081 A1 AR065081 A1 AR 065081A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
heterocyclyl
cycloalkylalkyl
heteroaryl
heteroarylalkyl
Prior art date
Application number
ARP080100362A
Other languages
Spanish (es)
Inventor
Qun Sun
Jianmin Fu
Duanjie Hou
Rajender Kamboj
Serguei Sviridov
Robert Fraser
Shifeng Liu
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of AR065081A1 publication Critical patent/AR065081A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Estos compuestos, sus estereoisomeros, enantiomeros, tautomeros o sus mezclas; una de sus sales, solvatos o profármacos farmacéuticamente aceptables son utiles para el tratamiento y/o la prevencion de enfermedades o condiciones patologicas mediadas por el canal de sodio, tales como dolor. Reivindicacion 1: Un compuesto de la formula (1), caracterizado porque: n es 1 a 4; el anillo A es un arilo fusionado o un heteroarilo fusionado; cada R1 está seleccionado, de modo independiente, del grupo que consiste en hidrogeno, alquilo, alquenilo, alquinilo, halo, haloalquilo, haloalquenilo, haloalquinilo, cicloalquilo, cicloalquilalquilo, cicloalquilalquenilo, cicloalquilalquinilo, arilo, aralquilo, aralquenilo, aralquinilo, heterociclilo, heterocicliIalquilo, heterociclilalquenilo, heterociclilalquinilo, heteroarilo, heteroarilalquilo, heteroarilalquenilo, heteroarilalquinilo,-R6-CN, -R6-NO2, -R6-OR5, -R6-N(R4)R5, -R6-S(O)pR4, -R6-C(O)R4, -R6-C(S)R4, -R6-C(R4)2C(O)R5, -R6-C(O)OR4, - R6-OC(O)R4, -R6-C(S)OR4, -R6-C(O)N(R4)R5, -R-C(S)N(R4)R5, -R6-N(R5)C(O)R4, -R6-N(R5)C(S)R4, -R6-N(R5)C(O)OR4, -R6-N(R5)C(S)OR4, -R6-N(R5)C(O)N(R4)R5, -R6-N(R5)C(S)N(R4)R5, -R6-N(R5)S(O)tR4, -R6-N(R5)S(O)tN(R4)R5, -R6-S(O)tN(R4)R5, -R6- N(R5)C(=NR5)N(R4)R5, y -R6-N(R5)C(N=C(R4)R5)N(R4)R5, en donde cada p es, de modo independiente, 0, 1 o 2 y cada t es, de modo independiente, 1 o 2, o dos grupos adyacentes R1, junto con los átomos de carbono o heteroanillos a los que están directamente unidos, pueden formar un anillo fusionado seleccionado de cicloalquilo, arilo, heterociclilo o heteroarilo, y los grupos R1 restantes, de estar presentes son como se describieron con anterioridad; R2 es hidrogeno, alquilo, alquenilo, alquinilo, haloalquilo, haloalquenilo, haloalquinilo, cicloalquilo, cicloalquilalquilo, cicloalquilalquenilo, arilo, aralquilo, aralquenilo, aralquinilo, heterociclilo, heterociclilalquilo, heterociclilalquenilo, heterociclilalquinilo, heteroarilo, heteroarilalquilo, heteroarilalquenilo o heteroarilalquinilo; R3 es hidrogeno, alquilo, alquenilo, alquinilo, haloalquilo, haloalquenilo, haloalquinilo, hidroxialquilo, cicloalquilo, cicloalquilalquilo, cicloalquilalquenilo, cicloalquilalquinilo, arilo, aralquilo, aralquenilo, aralquinilo, heterociclilo, heterociclilalquilo, heterociclilalquenilo, heterociclilalquinilo, heteroarilo, heteroarilalquilo, heteroarilalquenilo, heteroarilalquinilo, -R7-N(R4)R5 o -R7-N(R4)C(O)OR4; en donde el grupo cicloalquilo, cicloalquilalquilo, cicloalquilalquenilo, cicloalquilalquinilo, arilo, aralquilo, aralquenilo, aralquinilo, heterociclilo, heterociclilalquilo, heterociclilalquenilo, heterociclilalquinilo, heteroarilo, heteroarilalquilo, heteroarilalquenilo o heteroarilalquinilo puede estar opcionalmente sustituido con uno o varios sustituyentes seleccionados del grupo que consiste en alquilo, alquenilo, alquenilo, alquinilo, halo, haloalquilo, haloalquenilo, haloalquinilo, cicloalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, cicloalquilalquenilo opcionalmente sustituido, cicloalquilalquinilo opcionalmente sustituido, arilo opcionalmente sustituido, aralquilo opcionalmente sustituido, aralquenilo opcionalmente sustituido, aralquinilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, heterociclilalquilo opcionalmente sustituido, heterociclilalquenilo opcionalmente sustituido, heterociclilalquinilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroarilalquilo opcionalmente sustituido, heteroarilalquenilo opcionalmente sustituido, heteroarilalquinilo opcionalmente sustituido, R6-CN, -R6-NO2, -R6-OR5, -R6-OC(O)R4, -R6-OS(O)2R4, -R6-C(O)R4, -R6-C(O)OR4, -R6-C(O)N(R4)R5, -R6-N(R4)R5, -R6-N(R5)C(O)R4, -R6-N(R5)C(O)OR4, -R6-N(R5)C(O)N(R4)R5, -R6-N(R5)S(O)tR4, -R6-N[S(O)tR4]2, -R6-N(R5)C(=NR5)N(R4)R5, -R6-N(R5)C(=NR5)N(R4)CN, -R6-N(R5)C[=NC(O)OR4]-N(R4)-C(O)OR4, -R6-N(R5)-R7-N(R4)R5, -R6- N=C(OR4)R5, -R6-N=C(R4)R5, -R6-N(R5)-, -R6-OR5, -R6-S(O)pR4, y -R6-S(O)tN(R4)R5, en donde cada p es, de modo independiente, 0, 1 o 2 y cada t es, de modo independiente, 1 o 2, cada R4 y R5 está seleccionado, de modo independiente, del grupo que consiste en hidrogeno, alquilo, alquenilo, alquinilo, haloalquilo, hidroxialquilo, alcoxialquilo, cicloalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, arilo opcionalmente sustituido, aralquilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, heterociclilalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido y heteroarilalquilo opcionalmente sustituido; o R4 y R5, junto con el nitrogeno al que están unidos ambos, forman un N- heterociclilo opcionalmente sustituido o un N-heteroarilo opcionalmente suslituido; cada R6 es un enlace directo, una cadena de alquileno lineal o ramificada opcionalmente sustituida, una cadena de alquenileno lineal o ramificada opcionalmente sustituida o una cadena de alquinileno lineal o ramificada opcionalmente sustituida; y R7 es una cadena de alquileno lineal o ramificada, una cadena de alquenileno lineal o ramificada o una cadena de alquinileno lineal o ramificada; corno uno de sus estereoisomeros, enantiomeros, tautomeros o sus mezclas: o una de sus sales, solvatos o profármacos farmacéuticamente aceptables.These compounds, their stereoisomers, enantiomers, tautomers or mixtures thereof; one of its pharmaceutically acceptable salts, solvates or prodrugs are useful for the treatment and / or prevention of diseases or pathological conditions mediated by the sodium channel, such as pain. Claim 1: A compound of the formula (1), characterized in that: n is 1 to 4; ring A is a fused aryl or a fused heteroaryl; each R1 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, heterocyclyl, heterocyclyl, heterocyclyl, heterocyclyl, heterocyclyl heterocyclylalkenyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroarylalkyl, heteroarylalkyl, -R6-CN, -R6-NO2, -R6-OR5, -R6-N (R4) R5, -R6-S (O) pR4, -R6-C ( O) R4, -R6-C (S) R4, -R6-C (R4) 2C (O) R5, -R6-C (O) OR4, - R6-OC (O) R4, -R6-C (S ) OR4, -R6-C (O) N (R4) R5, -RC (S) N (R4) R5, -R6-N (R5) C (O) R4, -R6-N (R5) C (S ) R4, -R6-N (R5) C (O) OR4, -R6-N (R5) C (S) OR4, -R6-N (R5) C (O) N (R4) R5, -R6-N (R5) C (S) N (R4) R5, -R6-N (R5) S (O) tR4, -R6-N (R5) S (O) tN (R4) R5, -R6-S (O) tN (R4) R5, -R6- N (R5) C (= NR5) N (R4) R5, and -R6-N (R5) C (N = C (R4) R5) N (R4) R5, where each p is, independently, 0, 1 or 2 and each t is, independently, 1 or 2, or two adjacent groups R1, together with the carbon atoms or heteroanillos to which they are directly attached, can form a fused ring selected from cycloalkyl, aryl, heterocyclyl or heteroaryl, and the remaining R1 groups, if present are as described above; R2 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, aryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl or heteroarylalkynyl; R3 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, aryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, -R7-N (R4) R5 or -R7-N (R4) C (O) OR4; wherein the cycloalkyl, cycloalkylalkyl, cycloalkylalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkyl, heteroarylalkyl or heteroaryl group may be substituted by one or several of which may be selected from one heteroaryl or alkyl group alkyl, alkenyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkyl, optionally substituted heterocyclyl substituted, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkyl, h optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkyl, R6-CN, -R6-NO2, -R6-OR5, -R6-OC (O) R4, -R6-OS (O) 2R4, -R6 -C (O) R4, -R6-C (O) OR4, -R6-C (O) N (R4) R5, -R6-N (R4) R5, -R6-N (R5) C (O) R4 , -R6-N (R5) C (O) OR4, -R6-N (R5) C (O) N (R4) R5, -R6-N (R5) S (O) tR4, -R6-N [S (O) tR4] 2, -R6-N (R5) C (= NR5) N (R4) R5, -R6-N (R5) C (= NR5) N (R4) CN, -R6-N (R5) C [= NC (O) OR4] -N (R4) -C (O) OR4, -R6-N (R5) -R7-N (R4) R5, -R6- N = C (OR4) R5, -R6 -N = C (R4) R5, -R6-N (R5) -, -R6-OR5, -R6-S (O) pR4, and -R6-S (O) tN (R4) R5, where each p it is, independently, 0, 1 or 2 and each t is, independently, 1 or 2, each R4 and R5 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, heterocyclyl opci optionally substituted, optionally substituted heterocyclyl alkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; or R4 and R5, together with the nitrogen to which both are attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R6 is a direct bond, an optionally substituted linear or branched alkylene chain, an optionally substituted linear or branched alkenylene chain or an optionally substituted linear or branched alkynylene chain; and R7 is a linear or branched alkylene chain, a linear or branched alkenylene chain or a linear or branched alkynylene chain; as one of its stereoisomers, enantiomers, tautomers or mixtures thereof: or one of its pharmaceutically acceptable salts, solvates or prodrugs.

ARP080100362A 2007-01-29 2008-01-29 FUSIONATED QUINAZOLINONA AND PIRIMIDONA COMPOUNDS AND PHARMACEUTICAL COMPOSITION AR065081A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88712007P 2007-01-29 2007-01-29
US89118807P 2007-02-22 2007-02-22

Publications (1)

Publication Number Publication Date
AR065081A1 true AR065081A1 (en) 2009-05-13

Family

ID=39400881

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100362A AR065081A1 (en) 2007-01-29 2008-01-29 FUSIONATED QUINAZOLINONA AND PIRIMIDONA COMPOUNDS AND PHARMACEUTICAL COMPOSITION

Country Status (4)

Country Link
AR (1) AR065081A1 (en)
CL (1) CL2008000252A1 (en)
TW (1) TW200836743A (en)
WO (1) WO2008094909A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
JP2011530596A (en) * 2008-08-11 2011-12-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ Halofuginone analogs and their use for inhibition of tRNA synthetase
WO2010026177A1 (en) * 2008-09-05 2010-03-11 Neurosearch A/S 1,4-diaza-bicyclo [3.2.2] nonyl pyridine derivatives as nicotinic and monoamine receptor modulators
NZ594332A (en) * 2009-01-08 2013-09-27 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular disease
MX2011009821A (en) 2009-03-23 2012-01-25 Glenmark Pharmaceuticals Sa Isothiazolo-pyrimidinedione derivatives as trpa1 modulators.
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
SG174402A1 (en) 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as trpa1 modulators
AU2010227225A1 (en) 2009-03-23 2011-09-15 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as TRPA1 modulators
SMT201700456T1 (en) 2009-07-27 2017-11-15 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
US8722660B2 (en) 2010-02-17 2014-05-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP5858586B2 (en) 2010-07-02 2016-02-10 ギリアード サイエンシーズ， インコーポレイテッド Fused heterocyclic compounds as ion channel modulators
TWI577670B (en) 2011-05-10 2017-04-11 基利科學股份有限公司 Fused heterocyclic compounds as ion channel modulators
RU2014100744A (en) 2011-06-13 2015-07-20 Гленмарк Фармасьютикалс С.А. TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
JP2014517062A (en) 2011-06-22 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． Pharmaceutical composition comprising a TRPA1 antagonist and a β2 agonist
NO3175985T3 (en) 2011-07-01 2018-04-28
TWI478908B (en) 2011-07-01 2015-04-01 Gilead Sciences Inc Fused heterocyclic compound as ion channel regulator
WO2013014597A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
JP2015500278A (en) 2011-12-05 2015-01-05 グレンマーク ファーマシューティカルズ， エセ．アー． Pharmaceutical composition comprising a TRPA1 antagonist and an anticholinergic agent
US10155742B2 (en) 2012-01-13 2018-12-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX354014B (en) 2012-06-08 2018-02-08 Glenmark Pharmaceuticals Sa Amides of 2-amino-4-arylthiazole compounds and their salts.
WO2014093869A1 (en) 2012-12-13 2014-06-19 University Of Kansas 6-substituted quinazolinone inhibitors
FI3421462T3 (en) 2013-06-27 2023-06-26 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051244A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2926389A1 (en) 2013-10-15 2015-04-23 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
EP3119397B1 (en) 2014-03-19 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20190175599A1 (en) 2014-09-16 2019-06-13 Glemark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI698436B (en) 2014-12-30 2020-07-11 美商佛瑪治療公司 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
WO2016126935A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
EP3253738A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
CN114230571B (en) 2015-09-14 2025-07-08 无限药品股份有限公司 Solid forms of isoquinolinones, methods of making, compositions comprising, and methods of using the same
US10221191B2 (en) 2015-12-22 2019-03-05 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7514005B2 (en) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー Compounds that interact with the ras superfamily for the treatment of cancer, inflammatory diseases, rasopathy, and fibrotic diseases
EP3801525A4 (en) 2018-06-08 2022-03-23 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CA3142902A1 (en) * 2019-06-27 2020-12-30 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
CN111018793A (en) * 2019-12-10 2020-04-17 深圳市易瑞生物技术股份有限公司 Hypnone hapten as well as synthesis method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3047462A (en) * 1959-03-06 1962-07-31 Lab Jacques Logeais Soc D Expl Quinazolone anti-inflammatory composition
DE1695799C3 (en) * 1967-01-23 1974-10-17 Sumitomo Chemical Co., Ltd., Osaka (Japan) 5-chloro-3- square bracket to pyridin-2'-yl square bracket to -4- (3H) - quinazolinone
US3458513A (en) * 1967-11-02 1969-07-29 Wallace & Tiernan Inc 2-substituted-tetrahydro-halosulfamyl-quinazolinones
GB1583753A (en) * 1976-07-14 1981-02-04 Science Union & Cie Piperidine derivatives processes for their preparation and pharmaceutical compositions containing them
US20040152696A1 (en) * 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers

Also Published As

Publication number Publication date
CL2008000252A1 (en) 2008-03-14
WO2008094909A2 (en) 2008-08-07
WO2008094909A3 (en) 2010-03-11
TW200836743A (en) 2008-09-16

Similar Documents

Publication Publication Date Title
AR065081A1 (en) FUSIONATED QUINAZOLINONA AND PIRIMIDONA COMPOUNDS AND PHARMACEUTICAL COMPOSITION
AR065194A1 (en) PIRIDOPIRIMIDINONE COMPOUNDS OF USEFULNESS IN THE TREATMENT OF DISEASES OR PATHOLOGICAL CONDITIONS MEDIATED BY SODIUM CHANNELS
AR056317A1 (en) OXINDOL COMPOUNDS AND PHARMACEUTICAL COMPOSITION
ES2834333T3 (en) Pyrimidinyl tyrosine kinase inhibitors
AR059229A1 (en) PIPERIDINYL DERIVATIVES AS MODULATORS OF THE ACTIVITY OF THE CHEMIOKIN RECEPTOR
BR122012009489B8 (en) process for producing 2-ethoxy-1-{[2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazol- (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 7-carboxylate or a salt thereof, pharmaceutical composition, and use
AR053710A1 (en) SPIROHETEROCICLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
AR054560A1 (en) SPIROPIPERIDINE AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AR053713A1 (en) HETEROCICLICAL COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
AR065628A1 (en) TRICYCLE COMPOUNDS OF USEFULNESS IN THE TREATMENT OF IRON DISEASE IN THE ORGANISM
WO2014124651A1 (en) Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
BRPI0417208A (en) 8'-pyri (mi) dinyl dihydrospiro- [cycloalkylamine] -pyrimido [1,2-one] pyrimidin-6-one derivatives
MA28515B1 (en) INHIBITORS OF GSK-3
ECSP11011427A (en) PIPERIDINS REPLACED AS AN ANTIGONIST OF CCR3.
AU2016215033A1 (en) (9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
LU90317I2 (en) Tacrolimus and its pharmaceutically acceptable salts and derivatives
NZ626314A (en) 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
MA33832B1 (en) Isokinolinones and alternative quinolones
PE20090893A1 (en) PIRAZOLE DERIVATIVES AS ANTAGONISTS OF THE CCR2 AND / OR CCR5 RECEPTOR
ES2476422T3 (en) 3,5-substituted piperidine compounds as renin inhibitors
AR073497A1 (en) N-SULFONAMIDE POLYCLYCO PIRAZOLILO COMPOUNDS
CA2449402A1 (en) Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
EP1640367A4 (en) ISOQUINOLINE-1,3,4-TRIONE, SYNTHETIC PROCESS AND USE THEREOF
PE20030944A1 (en) INDOLYL-UREA DERIVED FROM THENOPYRIDINES USEFUL AS ANTIANGIOGENIC AGENTS AND PROCEDURES FOR THEIR USE
BRPI0812447A2 (en) PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS

Legal Events

Date Code Title Description
FB Suspension of granting procedure